Abstract:CONTEXT:There is concern that the widespread use of antiretroviral drugs to treat human immunodeficiency virus 1 (HIV-1) infection may result in the increased transmission of drug-resistant virus.OBJECTIVE:To determine the prevalence of drug resistance-conferring mutations and phenotypic resistance to antiretroviral agents in a cohort of individuals newly infected with HIV-1.DESIGN:Case series with genetic analyses of the HIV-1 plasma-derived pol gene using reverse transcriptase polymerase chain reaction followed by direct sequencing of polymerase chain reaction products. Phenotypic analysis was performed with a recombinant virus assay.SETTING AND PATIENTS:Eighty individuals referred, on average, 1.7 months after infection with HIV-1 to the Aaron Diamond AIDS Research Center between July 1995 and April 1999. Subjects were from large urban areas (65 from New York, NY; 11 from Los Angeles, Calif); 60 (75%) were white, and 75 (93.8%) were homosexual men.MAIN OUTCOME MEASURES:Prevalence of known resistance-conferring genotypes and reduced susceptibility to individual antiviral agents by phenotype.RESULTS:Thirteen individuals (16.3%) had genotypes associated with drug resistance to any antiretroviral agent. Virus with known resistance-conferring mutations to any nucleoside reverse transcriptase inhibitors was found in 10 individuals, to any nonnucleoside reverse transcriptase inhibitors in 6 subjects, and to any protease inhibitors in 2 cases. Multidrug-resistant virus was identified in 3 individuals (3.8%). Extensive polymorphism in the protease gene was identified. Interpretation of genotypes and phenotypes was concordant in 57 (85%) of the 67 cases in which both studies were performed.CONCLUSION:The prevalence of HIV-1 variants with known resistance-conferring genotypes to any antiretroviral agent in this cohort of 80 newly infected individuals is 16.3%. These data support expanded use of resistance testing in the setting of primary HIV-1 infection. Clinical trials should be initiated to establish whether therapy guided by resistance testing, compared with the use of empirical triple combination antiretroviral therapy, provides additional virological and immunological benefit when treating primary HIV-1 infection. Further efforts to expand the study of transmission of drug-resistant HIV-1 variants, particularly in cohorts with different epidemiological profiles, are indicated.

The Effect Of Drug-Injection Behavior On Genetic Evolution Of Hiv-1

Intrapatient Evolutionary Dynamics in an Individual Infected with HIV-1 CRF01_AE Who Experienced Periods of Treatment Failure

Preliminary Research on the Co-Infection of Human Immunodeficiency Virus and Hepatitis Virus in Intravenous Drug Users

Patterns of HIV-1 Evolution in Individuals with Differing Rates of CD4 T Cell Decline

Loss and Recovery of Genetic Diversity in Adapting Populations of HIV

Human-Immunodeficiency-Virus Type-1 Env and P17(Gag) Sequence Variation in Polymerase Chain Reaction-Positive, Seronegative Injection-Drug Users

The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users.

Recombination Rate and Selection Strength in HIV Intra-patient Evolution

The evolution of envelope function during coinfection with phylogenetically distinct human immunodeficiency virus

Host-specific Driving Force in Human Immunodeficiency Virus Type 1 Evolution in Vivo.

HIV-1 Drug Resistance in Newly Infected Individuals

Multiple-infection and recombination in HIV-1 within a longitudinal cohort of women

Frequent Cocaine Use is Associated With Larger HIV Latent Reservoir Size

Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion

Divergence of HIV-1 quasispecies in an epidemiologic cluster.

Infection With Dual-Tropic Human Immunodeficiency Virus Type 1 Variants Associated With Rapid Total T Cell Decline And Disease Progression In Injection Drug Users

Disentangling the impact of within-host evolution and transmission dynamics on the tempo of HIV-1 evolution

Drug Use is Associated with Anti-CD4 IgG-mediated CD4+ T Cell Death and Poor CD4+ T Cell Recovery in Viral-suppressive HIV-infected Individuals Under Antiretroviral Therapy

Maintaining low HIV type 1 env genetic diversity among injection drug users infected with a B/C recombinant and CRF01_AE HIV type 1 in southern China.

Dynamics of HIV-1 quasispecies diversity of participants on long-term antiretroviral therapy based on intrahost single-nucleotide variations

Gut microbiota profiling in injection drug users with and without HIV-1 infection in Puerto Rico